All In Biotech

BLA 761224 · Astrazeneca Ab

Tezspire

Tezepelumab-Ekko · Subcutaneous · Thymic Stromal Lymphopoietin Blocker

NovelPriority review

CDER novel approval, Dec 17, 2021: To treat severe asthma as an add-on maintenance therapy

Last checked: Nov 20, 2026Latest source record: Oct 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 17, 2021

Approved uses

3

Original approval plus efficacy supplements

Registered trials

49

21 Phase 3, 12 recruiting

FAERS reports

6,931

3,128 serious, 255 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 17, 2025.

TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. ( 1.1 ) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 ) • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) 1.1 Asthma TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. 1.2 Chronic Rhinosinusitis with Nasal Polyps TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

Mechanism: Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2λ that binds to human TSLP with a dissociation constant of 15.8 pM and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in inflammatory cascades. Airway and mucosal inflammation are important components of the pathogenesis of asthma and CRSwNP. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes, ILC2 cells) and mediators (e.g., histamine, eicosanoids,...

Therapeutic areas: Respiratory

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 17, 2025 Supplement 6 · Efficacy LabelLetter
  • Feb 1, 2023 Supplement 1 · Efficacy LetterLabel
  • Dec 17, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • TEZSPIRE · TEZEPELUMAB-EKKO 210MG/1.91ML(110MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tezepelumab" as an intervention, any sponsor and status, largest first.

All 49 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthma1,067
  • dyspnoea649
  • drug ineffective552
  • arthralgia551
  • product dose omission issue355
  • cough342
  • pneumonia294
  • fatigue273
  • headache259
  • back pain242
  • rash239
  • pain233

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20194
20208
20217
2022588
20231,252
20241,589
20251,785
20261,697

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tezspire (Tezepelumab-Ekko)

2024 spending

$184M

Beneficiaries

6,219

41,254 claims

Per beneficiary

$29,549

$2,241.12 per unit

View as table
YearSpending
2020$0
2021$0
2022$25,810,045
2023$88,238,002
2024$183,765,288

Part B: Tezspire (Tezepelumab-Ekko) · HCPCS J2356

2024 spending

$218M

Beneficiaries

7,618

59,000 claims

Per beneficiary

$28,676

2024 ASP limit $18.18 per unit

View as table
YearSpending
2020$0
2021$0
2022$31,796,362
2023$138,128,729
2024$218,453,021

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 91 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.